Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drotrecogin alfa in a subpopulation of severe sepsis
NCT00045760Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2002
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 32
01
Overview
Phase 4, randomised, double-blind trial in sepsis comparing Drotrecogin alfa (activated) with Placebo (2 arms). Started Sep 2002; status: completed.
02
Drugs
drotrecogin alfa
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT00045760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00045760.